Intravenous thrombolysis in stroke patients receiving rivaroxaban

European Journal of Neurology

Volumn 21, Issue 1, 2014, Pages

  Seiffge, D J ^a   Traenka, C ^a   Gensicke, H ^a   Tsakiris, D A ^a   Bonati, L H ^a   Peters, N ^a   Lyrer, P ^a   Engelter, S T ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Acute management of stroke; IV thrombolysis; Novel oral anticoagulants; Rivaroxaban; Stroke

Indexed keywords

ALTEPLASE; RIVAROXABAN;

AGED; APHASIA; BLOOD CLOT LYSIS; BRAIN INFARCTION; CASE REPORT; CEREBROVASCULAR ACCIDENT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEMIPARESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; MIDDLE CEREBRAL ARTERY OCCLUSION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT TRANSPORT; PRIORITY JOURNAL; STROKE PATIENT; THALAMUS; THROMBIN TIME; TIME TO TREATMENT;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; MORPHOLINES; STROKE; THIOPHENES; THROMBOLYTIC THERAPY;

EID: 84890097656     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12285     Document Type: Letter

References (11)

1. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol 2012; 11: 1066-1081.
2. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947.
3. Brouns R, Van Hooff RJ, De Smedt A, et al. Acute stroke management in patients taking dabigatran. CNS Neurosci Ther 2012; 18: 616-622.
4. Chong CA, Chiu L. Dabigatran and acute stroke thrombolysis. Cerebrovasc Dis 2010; 30: 202.
5. De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010; 30: 533-534.
6. Pfeilschifter W, Abruscato M, Hovelmann S, Baas H. Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases. Case Rep Neurol 2013; 5: 56-61.
7. Steiner T, Bohm M, Dichgans M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102: 399-412.
8. Harenberg J, Kraemer R. Measurement of the new anticoagulants. Thromb Res 2012; 129(Suppl 1): S106-S113.
9. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686.
10. Harenberg J, Du S, Kramer S, et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. Semin Thromb Hemost 2013; 39: 66-71.
11. Mazya MV, Lees KR, Markus R, et al. Safety of IV thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol 2013; doi: 10.1002/ana.23924 [Epub ahead of print].